### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, D | D.C. 20549 |
|---------------|------------|
|---------------|------------|

| Check this box if no longer subject to<br>Section 16. Form 4 or Form 5 | STATEMENT OF CHA      |
|--|-----------------------|
| obligations may continue. See  |                       |
| Instruction 1(b).  | Filed pursuant to Sec |

## ANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person LILLY ENDOWMENT INC      |   |  |        |   |                            | LILLY ELI & CO [ LLY ]                                      |   |     |              |   |                        |   |                       |                        | all app                                    |   | y Feiso<br>X   | 10% C   | Owner                                 |
|--|---|--|--------|---|----------------------------|---|---|-----|--------------|---|------------------------|---|-----------------------|------------------------|--|---|--|---|---------------------------------------|
| (Last)<br>2801 NO  | (Fii<br>RTH MERI  | rst) (                                     | Middle | e)  |                            | 3. Date of Earliest Transaction (Month/Day/Year) 02/28/2019 |   |     |              |   |                        |   |                       |                        | Officer (give title below)                 |   | Other<br>below   |   | (specify                              |
| (Street) INDIANAPOLIS IN 46208-0068  (City) (State) (Zip)        |   |  |        |   | _   4. li                  | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |   |     |              |   |                        |   |                       | 6. Indiv<br>_ine)<br>X | <b>'</b>                                   |   |  |   |                                       |
|  |   | Tabl                                       | e I -  | Non-Deriv                                 | vative                     | Sec   | uritie  | s A | cquir        | ed, D   | isposed o              | f, or E   | Benefic               | ially                  | Owne                                       | ed  |  |   |                                       |
| 1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/ |   |  |        | ·   | Execution [                |   | tion Date,  |     |              | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and |                        |   | d 5) Sec<br>Ben       |                        | ount of<br>ities<br>icially<br>d Following | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4)                               |  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |                                       |
|  |   |  |        |   |                            |   |   |     | Code         | v   | Amount                 | (A) or<br>(D)   | Price                 |                        | Trans                                      | ransaction(s)<br>nstr. 3 and 4)   |  |   | (111341.4)                            |
| Common   | ommon Stock 02/28/2   |  |        |   | 019                        | .9  |   |     | S            |   | 166,800                | D   | \$126.                | 58 <sup>(1)</sup> 11   |  | 117,258,504   |  | )   |                                       |
| Common   | mmon Stock 02/28/20   |  |        |   | 019                        | .9  |   |     | S            |   | 33,200                 | D   | \$127.4               | 54 <sup>(2)</sup>      | 117,225,304                                |   | ]  | )   |                                       |
|  |   | Та   | ble I  |   |                            |   |   |     |              |   | posed of,<br>convertib |   |                       |                        | vned                                       |   |  |   |                                       |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)              | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | Execu  | eemed<br>ution Date,<br>,<br>th/Day/Year) | 4.<br>Transa<br>Code<br>8) |   | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3, 4<br>and 5) |     | Expi         | ate Exer<br>ration I<br>nth/Day                                   |                        | 7. Title<br>Amour<br>Securi<br>Underl<br>Deriva<br>Securi<br>and 4) | nt of<br>ties<br>ying | Deriv<br>Secu          | Price of<br>ivative<br>curity<br>str. 5)   | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | Ownershi<br>Form:<br>Direct (D)<br>or Indirec<br>(I) (Instr. 4 | m:<br>ect (D)<br>ndirect  | Beneficial<br>Ownership<br>(Instr. 4) |
|  |   |  |        |   | Code                       | v   | (A)   | (D) | Date<br>Exer | cisable   | Expiration<br>Date     | Title   | of<br>Shares          |                        |  |   |  |   |                                       |

### **Explanation of Responses:**

### Remarks:

/s/Peter A. Buck, Vice President for Investments, on 03/01/2019 behalf of Lilly Endowment Inc.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$126.1837 to \$127.1198, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

<sup>2.</sup> The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$127.2472 to \$127.6522, inclusive.